TY  - JOUR
A1  - Santos, Laila R. B. dos
A1  - Fleming, Ingrid
T1  - Role of cytochrome P450-derived, polyunsaturated fatty acid mediators in diabetes and the metabolic syndrome
T2  - Prostaglandins & other lipid mediators
N2  - Over the last decade, cases of metabolic syndrome and type II diabetes have increased exponentially. Exercise and ω-3 polyunsaturated fatty acid (PUFA)-enriched diets are usually prescribed but no therapy is effectively able to restore the impaired glucose metabolism, hypertension, and atherogenic dyslipidemia encountered by diabetic patients. PUFAs are metabolized by different enzymes into bioactive metabolites with anti- or pro-inflammatory activity. One important class of PUFA metabolizing enzymes are the cytochrome P450 (CYP) enzymes that can generate a series of bioactive products, many of which have been attributed protective/anti-inflammatory and insulin-sensitizing effects in animal models. PUFA epoxides are, however, further metabolized by the soluble epoxide hydrolase (sEH) to fatty acid diols. The biological actions of the latter are less well understood but while low concentrations may be biologically important, higher concentrations of diols derived from linoleic acid and docosahexaenoic acid have been linked with inflammation. One potential application for sEH inhibitors is in the treatment of diabetic retinopathy where sEH expression and activity is elevated as are levels of a diol of docosahexaenoic acid that can induce the destabilization of the retina vasculature.
KW  - Cytochrome P450 enzymes
KW  - Insulin resistance
KW  - Metabolic syndrome
KW  - Polyunsaturated fatty acids
Y1  - 2019
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/77750
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-777507
SN  - 1098-8823
VL  - 148.2020
IS  - 106407
PB  - Elsevier
CY  - New York, NY
ER  -